FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378783776> ?p ?o ?g. }

• W4378783776 abstract "Background Immune-evading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are emerging continuously. The clinical effectiveness of monoclonal antibody agents that exhibit decreased in vitro activity against SARS-CoV-2 variants needs to be elucidated. Methods A nationwide, multicenter, retrospective cohort study was designed to evaluate the effectiveness of regdanvimab, an anti-SARS-CoV-2 monoclonal antibody agent. Regdanvimab was prescribed in South Korea before and after the emergence of the delta variant, against which the in vitro activity of regdanvimab was decreased but present. Mild to moderate coronavirus 2019 (COVID-19) patients with risk factors for disease progression who were admitted within seven days of symptom onset were screened in four designated hospitals between December 2020 and September 2021. The primary outcomes, O 2 requirements and progression to severe disease within 21 days of admission, were compared between the regdanvimab and supportive care groups, with a subgroup analysis of delta variant–confirmed patients. Results A total of 2,214 mild to moderate COVID-19 patients were included, of whom 1,095 (49.5%) received regdanvimab treatment. In the analysis of the total cohort, significantly fewer patients in the regdanvimab group than the supportive care group required O 2 support (18.4% vs. 27.1%, P &lt; 0.001) and progressed to severe disease (4.0% vs. 8.0%, P &lt; 0.001). In the multivariable analysis, regdanvimab was significantly associated with a decreased risk for O 2 support (HR 0.677, 95% CI 0.561–0.816) and progression to severe disease (HR 0.489, 95% CI 0.337–0.709). Among the 939 delta-confirmed patients, O 2 support (21.5% vs. 23.5%, P = 0.526) and progression to severe disease (4.2% vs. 7.3%, P = 0.055) did not differ significantly between the regdanvimab and supportive care groups. In the multivariable analyses, regdanvimab treatment was not significantly associated with a decreased risk for O 2 support (HR 0.963, 95% CI 0.697–1.329) or progression to severe disease (HR 0.665, 95% CI 0.349–1.268) in delta-confirmed group. Conclusions Regdanvimab treatment effectively reduced progression to severe disease in the overall study population, but did not show significant effectiveness in the delta-confirmed patients. The effectiveness of dose increment of monoclonal antibody agents should be evaluated for variant strains exhibiting reduced susceptibility." @default.
• W4378783776 created "2023-06-01" @default.
• W4378783776 creator A5001791857 @default.
• W4378783776 creator A5002070570 @default.
• W4378783776 creator A5018893019 @default.
• W4378783776 creator A5019554427 @default.
• W4378783776 creator A5022048603 @default.
• W4378783776 creator A5023865884 @default.
• W4378783776 creator A5025016732 @default.
• W4378783776 creator A5026875958 @default.
• W4378783776 creator A5027091192 @default.
• W4378783776 creator A5028595069 @default.
• W4378783776 creator A5036635540 @default.
• W4378783776 creator A5041486786 @default.
• W4378783776 creator A5043417561 @default.
• W4378783776 creator A5046651134 @default.
• W4378783776 creator A5055224951 @default.
• W4378783776 creator A5067794537 @default.
• W4378783776 creator A5074692042 @default.
• W4378783776 creator A5075278707 @default.
• W4378783776 creator A5078775403 @default.
• W4378783776 creator A5085582030 @default.
• W4378783776 date "2023-05-15" @default.
• W4378783776 modified "2023-10-14" @default.
• W4378783776 title "Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study" @default.
• W4378783776 cites W2086570641 @default.
• W4378783776 cites W3046186724 @default.
• W4378783776 cites W3111431752 @default.
• W4378783776 cites W3119881634 @default.
• W4378783776 cites W3125712166 @default.
• W4378783776 cites W3137464688 @default.
• W4378783776 cites W3178120763 @default.
• W4378783776 cites W3182094313 @default.
• W4378783776 cites W3200766981 @default.
• W4378783776 cites W3210342412 @default.
• W4378783776 cites W3211924228 @default.
• W4378783776 cites W3215399721 @default.
• W4378783776 cites W4210311296 @default.
• W4378783776 cites W4210404402 @default.
• W4378783776 cites W4212988737 @default.
• W4378783776 cites W4220848096 @default.
• W4378783776 cites W4221084154 @default.
• W4378783776 cites W4225159783 @default.
• W4378783776 cites W4225553089 @default.
• W4378783776 cites W4226087845 @default.
• W4378783776 cites W4226148899 @default.
• W4378783776 cites W4226181138 @default.
• W4378783776 cites W4280565215 @default.
• W4378783776 cites W4282935642 @default.
• W4378783776 cites W4283031357 @default.
• W4378783776 cites W4296999298 @default.
• W4378783776 cites W4307953698 @default.
• W4378783776 cites W4311575747 @default.
• W4378783776 cites W4313627377 @default.
• W4378783776 cites W4322773298 @default.
• W4378783776 doi "https://doi.org/10.3389/fcimb.2023.1192512" @default.
• W4378783776 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37256107" @default.
• W4378783776 hasPublicationYear "2023" @default.
• W4378783776 type Work @default.
• W4378783776 citedByCount "0" @default.
• W4378783776 crossrefType "journal-article" @default.
• W4378783776 hasAuthorship W4378783776A5001791857 @default.
• W4378783776 hasAuthorship W4378783776A5002070570 @default.
• W4378783776 hasAuthorship W4378783776A5018893019 @default.
• W4378783776 hasAuthorship W4378783776A5019554427 @default.
• W4378783776 hasAuthorship W4378783776A5022048603 @default.
• W4378783776 hasAuthorship W4378783776A5023865884 @default.
• W4378783776 hasAuthorship W4378783776A5025016732 @default.
• W4378783776 hasAuthorship W4378783776A5026875958 @default.
• W4378783776 hasAuthorship W4378783776A5027091192 @default.
• W4378783776 hasAuthorship W4378783776A5028595069 @default.
• W4378783776 hasAuthorship W4378783776A5036635540 @default.
• W4378783776 hasAuthorship W4378783776A5041486786 @default.
• W4378783776 hasAuthorship W4378783776A5043417561 @default.
• W4378783776 hasAuthorship W4378783776A5046651134 @default.
• W4378783776 hasAuthorship W4378783776A5055224951 @default.
• W4378783776 hasAuthorship W4378783776A5067794537 @default.
• W4378783776 hasAuthorship W4378783776A5074692042 @default.
• W4378783776 hasAuthorship W4378783776A5075278707 @default.
• W4378783776 hasAuthorship W4378783776A5078775403 @default.
• W4378783776 hasAuthorship W4378783776A5085582030 @default.
• W4378783776 hasBestOaLocation W43787837761 @default.
• W4378783776 hasConcept C126322002 @default.
• W4378783776 hasConcept C167135981 @default.
• W4378783776 hasConcept C201903717 @default.
• W4378783776 hasConcept C203014093 @default.
• W4378783776 hasConcept C2779134260 @default.
• W4378783776 hasConcept C3007834351 @default.
• W4378783776 hasConcept C3008058167 @default.
• W4378783776 hasConcept C524204448 @default.
• W4378783776 hasConcept C71924100 @default.
• W4378783776 hasConcept C72563966 @default.
• W4378783776 hasConceptScore W4378783776C126322002 @default.
• W4378783776 hasConceptScore W4378783776C167135981 @default.
• W4378783776 hasConceptScore W4378783776C201903717 @default.
• W4378783776 hasConceptScore W4378783776C203014093 @default.
• W4378783776 hasConceptScore W4378783776C2779134260 @default.
• W4378783776 hasConceptScore W4378783776C3007834351 @default.
• W4378783776 hasConceptScore W4378783776C3008058167 @default.
• W4378783776 hasConceptScore W4378783776C524204448 @default.

• next